Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Zastaprazan Citrate

Inclusion Criteria: * Patients who receive their first prescription for zastaprazan citrate in accordance with the approved prescribing information after execution of the study agreement * Patients who have received an explanation of the study and voluntarily signed the informed consent form. Exclusion Criteria: * Patients with hypersensitivity or a history of hypersensitivity to zastaprazan citrate or any component of the product. * atients currently receiving products containing atazanavir, nelfinavir, or rilpivirine. * Patients who are pregnant or breastfeeding. * Patients with hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. This exclusion criterion does not apply to the orally disintegrating tablet formulation.